Drug intelligence / Profile preview

3H-2000

Development stage: Preclinical
Lead developer: 3H Pharmaceuticals
Modality: Small Molecules

Overview

3H-2000 (also known as Project 2000) is a small molecule drug candidate under development by 3H Pharmaceuticals for the treatment of cancer. Currently in the early discovery or preclinical stage, the specific molecular target and mechanism of action for 3H-2000 have not been publicly disclosed. It is part of 3H Pharmaceuticals' oncology pipeline, which includes several other small molecule and biologic candidates aimed at addressing various malignancies.

Beyond the preview

Go deeper on 3H-2000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3H-2000.

Explore the full profile